CLINICAL TRIALS PROFILE FOR CELECOXIB; TRAMADOL HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for CELECOXIB; TRAMADOL HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00290901 ↗ | Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain. | Completed | Pfizer | Phase 4 | 2006-03-01 | This study investigates if Celebrex is as effective as tramadol hydrochloride (Ultram) for patients with chronic low back pain, when administered over a 6-week period. |
| NCT00290901 ↗ | Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain. | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 | 2006-03-01 | This study investigates if Celebrex is as effective as tramadol hydrochloride (Ultram) for patients with chronic low back pain, when administered over a 6-week period. |
| NCT00348452 ↗ | A Study Comparing the Effectiveness and Safety of Extended Release Tramadol HCl at 100 mg, 200 mg and 300 mg Doses to Placebo for the Treatment of Moderate to Severe Pain Due to Osteoarthritis (OA) | Completed | Bausch Health Americas, Inc. | Phase 3 | 2002-09-01 | The purpose of this study is to compare the analgesic efficacy and safety of tramadol HCl ER 100 mg, 200 mg and 300 mg once a day (QD), with placebo in patients with moderate to severe pain due to OA. For the purposes of this study, celecoxib will serve as a positive control to validate the sensitivity of the model. The study hypothesis is that tramadol HCl ER is safe and effective in the treatment of moderate to severe pain due to OA. |
| NCT00348452 ↗ | A Study Comparing the Effectiveness and Safety of Extended Release Tramadol HCl at 100 mg, 200 mg and 300 mg Doses to Placebo for the Treatment of Moderate to Severe Pain Due to Osteoarthritis (OA) | Completed | Valeant Pharmaceuticals International, Inc. | Phase 3 | 2002-09-01 | The purpose of this study is to compare the analgesic efficacy and safety of tramadol HCl ER 100 mg, 200 mg and 300 mg once a day (QD), with placebo in patients with moderate to severe pain due to OA. For the purposes of this study, celecoxib will serve as a positive control to validate the sensitivity of the model. The study hypothesis is that tramadol HCl ER is safe and effective in the treatment of moderate to severe pain due to OA. |
| NCT00662558 ↗ | A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain | Completed | Pfizer | Phase 3 | 2008-01-01 | To compare the analgesic effectiveness of celecoxib and tramadol in subjects with Chronic Low Back Pain measured by the Numerical Rating Scale (NRS-Pain) at Week 6 |
| NCT00662558 ↗ | A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 3 | 2008-01-01 | To compare the analgesic effectiveness of celecoxib and tramadol in subjects with Chronic Low Back Pain measured by the Numerical Rating Scale (NRS-Pain) at Week 6 |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CELECOXIB; TRAMADOL HYDROCHLORIDE
Condition Name
Clinical Trial Locations for CELECOXIB; TRAMADOL HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for CELECOXIB; TRAMADOL HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for CELECOXIB; TRAMADOL HYDROCHLORIDE
Sponsor Name
